Home / Treatments / Growth Hormone Therapy
Growth Hormone Therapy denials: what the review data shows
Independent reviewers have decided 107 published cases where an insurer denied Growth Hormone Therapy — and they overturned the insurer 49.5% of the time. A denial for Growth Hormone Therapy is a starting position, not a final answer.
Published decisions
107
2001–2026
Overturned
49.5%
53 denials reversed
By condition
Published outcomes when Growth Hormone Therapy was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Idiopathic Short Stature | 34 | 64.7% |
| Short Stature | 18 | 38.9% |
| Growth Hormone Deficiency | 17 | 58.8% |
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Growth Hormone Therapywhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.